STOCK TITAN

Gilead Sciences (GILD) Financials

GILD NASDAQ
Trailing 12 months to September 30, 2026
Revenue $31.0B +6.5% YoY
Net Income -$3.9B -147.6% YoY
EPS (Diluted) -$3.16 -149.0% YoY
Free Cash Flow $13.8B +50.4% YoY
Market Cap $211.2B as of Nov 17, 2026
Price / Sales 6.8x on $31.0B revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 16.2x on $13.0B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Oct 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GILD SEC filings page.

Gilead Sciences Inc (GILD) reported $31.0B in revenue over the twelve months to Sep 30, 2026, up 6.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GILD FY2025

Near-flat sales support a sharp profit rebound, while cash generation remains steadier than reported earnings.

Cash conversion exposes earnings volatility: in FY2024, net income fell 91.5% while operating cash flow rose 35.2%; in FY2025, net income rose 1672.9% while operating cash flow fell 7.5%. The contrast means reported profit was heavily influenced by below-operating-cash items or timing, whereas the underlying cash stream moved much less dramatically.

The FY2025 rebound occurred below gross profit: gross profit reached $23.2B after rising only 3.1%, but operating income reached $10.0B after FY2024's $1.66B. With revenue up just 2.4%, the change points to normalization in operating expenses or other below-gross-profit items rather than a volume-driven expansion.

Capital intensity is modest, with capital expenditures at 1.9% of revenue and free cash flow of $9.46B in FY2025. At the same time, liabilities fell 8.4% and debt-to-equity improved to 1.0x, so the business converted substantial cash while reducing balance-sheet leverage.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 66 / 100
Financial Health Score 66/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Gilead Sciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
79

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Gilead Sciences Inc scores 79/100 on it among other operating companies.

Growth
45

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Gilead Sciences Inc scores 45/100 on it among other operating companies.

Leverage
58

Gilead Sciences Inc's net debt of $14.6B, being $22.1B of long-term debt less $7.6B of cash, came to 1.14 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Gilead Sciences Inc scores 58/100 among other operating companies measured the same way.

Liquidity
45

Gilead Sciences Inc held $1.55 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.55. Liquidity ranks operating companies on that ratio, and Gilead Sciences Inc scores 45/100 among other operating companies.

Cash Flow
95

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Gilead Sciences Inc scores 95/100 on it among other operating companies.

Returns
74

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Gilead Sciences Inc scores 74/100 on it among other operating companies.

Altman Z-Score Safe
5.01

Gilead Sciences Inc scores 5.01, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $211.2B against total liabilities of $36.3B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong
8/9

Gilead Sciences Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed
1.18x

For every $1 of reported earnings, Gilead Sciences Inc generates $1.18 in operating cash flow ($10.0B OCF vs $8.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe
9.79x

Gilead Sciences Inc earns $9.79 in operating income for every $1 of interest expense ($10.0B vs $1.0B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$8.3B
YoY+6.8%
QoQ+6.4%
5Y CAGR+2.3%
10Y CAGR+1.0%

Gilead Sciences Inc generated $8.3B in revenue in Q3 2026. This represents an increase of 6.8% from the same quarter a year earlier. Against the prior quarter it is up 6.4%.

EBITDA
$3.6B
YoY+5.2%
QoQn/m
5Y CAGR-3.8%

Gilead Sciences Inc's EBITDA was $3.6B in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.2% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
$2.4B
YoY-20.4%
QoQn/m
5Y CAGR-1.3%
10Y CAGR-3.1%

Gilead Sciences Inc reported $2.4B in net income in Q3 2026. This represents a decrease of 20.4% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
$1.94
YoY-20.2%
QoQn/m
5Y CAGR-1.1%
10Y CAGR-2.5%

Gilead Sciences Inc earned $1.94 per diluted share (EPS) in Q3 2026. This represents a decrease of 20.2% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
$4.8B
YoY+21.1%
QoQ+39.8%
5Y CAGR+9.0%
10Y CAGR+1.4%

Gilead Sciences Inc generated $4.8B in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 21.1% from the same quarter a year earlier. Against the prior quarter it is up 39.8%.

Cash & Debt
$6.4B
YoY-12.2%
QoQ+102.5%
5Y CAGR+8.1%
10Y CAGR-4.1%

Gilead Sciences Inc held $6.4B in cash against $23.8B in long-term debt as of Q3 2026.

Dividends Per Share
$0.82
YoY+3.8%
QoQ0.0%
5Y CAGR+2.9%
10Y CAGR+5.7%

Gilead Sciences Inc paid $0.82 per share in dividends in Q3 2026. This represents an increase of 3.8% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding
1.24B
YoY0.0%
QoQ0.0%
5Y CAGR-0.2%
10Y CAGR-0.6%

Gilead Sciences Inc had 1.24B shares outstanding in Q3 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Margins & Returns

Gross Margin
81.1%
YoY+1.3pp
QoQ+1.3pp
5Y change-2.5pp
10Y change-2.6pp

Gilead Sciences Inc's gross margin was 81.1% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.3 percentage points.

Operating Margin
41.7%
YoY-1.1pp
5Y change-10.1pp

Gilead Sciences Inc's operating margin was 41.7% in Q3 2026, reflecting core business profitability. This is down 1.1 percentage points from the same quarter a year earlier.

Net Margin
29.3%
YoY-10.0pp
5Y change-5.7pp
10Y change-15.1pp

Gilead Sciences Inc's net profit margin was 29.3% in Q3 2026, showing the share of revenue converted to profit. This is down 10.0 percentage points from the same quarter a year earlier.

Return on Equity
18.6%
YoY+4.5pp
QoQ+107.4pp
5Y change+6.6pp
10Y change-1.1pp

Gilead Sciences Inc's quarterly ROE was 18.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 4.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 107.4 percentage points.

Capital Allocation

R&D Spending
$1.6B
YoY+19.5%
QoQ-8.8%
5Y CAGR+7.9%

Gilead Sciences Inc invested $1.6B in research and development in Q3 2026. This represents an increase of 19.5% from the same quarter a year earlier. Against the prior quarter it is down 8.8%.

Share Buybacks
$370.0M
YoY-14.9%
QoQ+4.2%
5Y CAGR+20.6%
10Y CAGR-9.5%

Gilead Sciences Inc spent $370.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 14.9% from the same quarter a year earlier. Against the prior quarter it is up 4.2%.

Capital Expenditures
$237.0M
YoY+61.2%
QoQ+69.3%
5Y CAGR+11.3%
10Y CAGR+1.8%

Gilead Sciences Inc invested $237.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 61.2% from the same quarter a year earlier. Against the prior quarter it is up 69.3%.

GILD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GILD quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$8.3B+6.8%$7.8B+10.2%$7.0B+4.4%$7.9B+4.7%$7.8B+3.0%$7.1B+1.8%$6.7B-0.3%$7.6B+6.4%
Cost of Revenue$1.6B+0.1%$1.6B+5.2%$1.4B-6.2%$1.6B+2.7%$1.6B-0.3%$1.5B-2.8%$1.5B-0.8%$1.6B-24.4%
Gross Profit$6.7B+8.5%$6.2B+11.5%$5.5B+7.6%$6.3B+5.2%$6.2B+3.8%$5.6B+3.2%$5.1B-0.1%$6.0B+19.2%
R&D Expenses$1.6B+19.5%$1.8B+18.3%$1.4B-0.5%$1.6B-3.5%$1.3B-3.5%$1.5B+10.4%$1.4B-9.3%$1.6B+16.6%
SG&A Expenses$1.6B+20.9%$1.9B+40.7%$1.5B+15.3%$1.8B-5.9%$1.4B-5.3%$1.4B-0.9%$1.3B-8.5%$1.9B+18.6%
Operating Income$3.5B+4.1%-$10.4B-520.1%$2.6B+15.6%$2.0B-19.1%$3.3B+274.7%$2.5B-6.4%$2.2Bn/m$2.5B+52.1%
EBITDA$3.6B+5.2%-$10.3B-501.1%$2.7B+14.8%$2.1B-18.6%$3.4B+248.0%$2.6B-6.4%$2.3Bn/m$2.5B+10.6%
Interest Expense$269.0M+5.1%$247.0M-2.8%$240.0M-7.7%$254.0M+2.4%$256.0M+7.6%$254.0M+7.2%$260.0M+2.4%$248.0M-1.6%
Income Tax$634.0M+7.6%$242.0M-48.3%$559.0M+67.4%-$105.0M-127.3%$589.0Mn/m$468.0M+6.8%$334.0Mn/m$385.0M+63.1%
Net Income$2.4B-20.4%-$10.5B-635.5%$2.0B+53.7%$2.2B+22.4%$3.1B+143.6%$2.0B+21.4%$1.3Bn/m$1.8B+24.7%
EPS (Basic)$1.96-20.3%-$8.45-638.2%$1.63+53.8%$1.76+23.9%$2.46+146.0%$1.57+21.7%$1.06n/m$1.42+23.5%
EPS (Diluted)$1.94-20.2%-$8.45-641.7%$1.61+54.8%$1.74+22.5%$2.43+143.0%$1.56+20.9%$1.04n/m$1.42+25.7%
Diluted Shares (Avg)1.25B-0.2%1.24B-1.0%1.25B-0.4%N/A1.25B0.0%1.25B+0.3%1.26B+1.0%N/A

GILD Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GILD quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$51.4B-12.2%$49.4B-11.4%$56.3B-0.3%$59.0B0.0%$58.5B+7.4%$55.7B+4.0%$56.4B+0.3%$59.0B-5.0%
Current Assets$16.6B-7.4%$13.9B-5.3%$18.6B+10.3%$18.3B-4.3%$17.9B+20.9%$14.7B+19.5%$16.9B+20.4%$19.2B+19.2%
Cash & Equivalents$6.4B-12.2%$3.2B-38.2%$7.6B-3.8%$7.6B-24.3%$7.3B+45.5%$5.1B+85.6%$7.9B+68.0%$10.0B+64.2%
Short-Term Investments$0-100.0%$0-100.0%$15.0Mn/m$68.0Mn/m$19.0Mn/m$69.0Mn/m$0n/m$0-100.0%
Inventory$1.9B+6.2%$2.0B+7.0%$1.9B+8.8%$1.8B+3.7%$1.8B-4.5%$1.8B-9.9%$1.8B-5.1%$1.7B-4.3%
Accounts Receivable$5.0B-1.7%$5.1B+5.7%$4.7B+8.0%$4.9B+11.2%$5.1B+11.1%$4.8B+2.5%$4.4B-6.0%$4.4B-5.2%
Long-Term Investments$0-100.0%$0-100.0%$983.0Mn/m$3.0Bn/m$2.0Bn/m$1.9Bn/m$0n/m$0-100.0%
Goodwill$8.3B0.0%$8.3B0.0%$8.3B0.0%$8.3B0.0%$8.3B0.0%$8.3B0.0%$8.3B0.0%$8.3B0.0%
Total Liabilities$38.4B+3.7%$37.5B+4.1%$32.8B-12.1%$36.3B-8.4%$37.0B+2.6%$36.0B+2.1%$37.3B-3.8%$39.7B+0.9%
Current Liabilities$12.0B-2.4%$11.0B-1.5%$9.5B-23.2%$11.8B-1.6%$12.3B+4.9%$11.2B+3.8%$12.3B-5.2%$12.0B+6.4%
Non-Current Liabilities$26.4B+6.8%$26.5B+6.7%$23.3B-6.6%$24.5B-11.4%$24.7B+1.5%$24.9B+1.4%$24.9B-3.1%$27.7B-1.3%
Long-Term Debt$23.8B+7.6%$23.8B+7.6%$20.9B-5.8%$22.1B-11.1%$22.1B+3.3%$22.1B+2.8%$22.1B+2.9%$24.9B+7.4%
Total Equity$13.0B-39.5%$11.8B-39.9%$23.5B+22.7%$22.7B+17.4%$21.5B+16.6%$19.7B+7.6%$19.2B+9.3%$19.3B-15.3%
Retained Earnings$3.1B-75.8%$2.2B-80.6%$14.1B+29.3%$13.7B+19.4%$12.8B+15.8%$11.3B+1.4%$10.9B+2.6%$11.5B-29.5%

GILD Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GILD quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$5.0B+22.6%$3.6B+332.0%$2.5B+44.8%$3.3B+11.8%$4.1B-4.7%$827.0M-37.6%$1.8B-20.8%$3.0B+37.2%
Depreciation & Amortization$132.0M+46.7%$98.0M+5.4%$93.0M-4.1%$90.0M-5.3%$90.0M-4.3%$93.0M-5.1%$97.0M+3.2%$95.0M-86.3%
Stock-Based CompensationN/AN/A$218.0M+4.3%N/AN/AN/A$209.0M+11.8%N/A
Capital Expenditures$237.0M+61.2%$140.0M+30.8%$117.0M+12.5%$205.0M+39.5%$147.0M+4.3%$107.0M-17.7%$104.0M-1.0%$147.0M-31.6%
Free Cash Flow$4.8B+21.1%$3.4B+376.8%$2.4B+46.8%$3.1B+10.4%$4.0B-5.0%$720.0M-39.7%$1.7B-21.8%$2.8B+44.7%
Investing Cash Flow-$244.0Mn/m-$10.3Bn/m$1.8Bn/m-$1.8Bn/m-$427.0Mn/m-$2.1Bn/m-$415.0Mn/m-$225.0Mn/m
Financing Cash Flow-$1.5Bn/m$2.3Bn/m-$4.2Bn/m-$1.3B-155.9%-$1.5Bn/m-$1.6Bn/m-$3.4Bn/m$2.3Bn/m
Dividends Paid$1.0B+3.4%$1.0B+3.5%$1.0B+3.0%$994.0M+2.2%$1.0B+2.2%$994.0M+2.3%$1.0B+2.0%$973.0M+3.2%
Share Buybacks$370.0M-14.9%$355.0M-32.6%$419.0M-42.6%$230.0M-34.3%$435.0M+45.0%$527.0M+427.0%$730.0M+82.5%$350.0M+133.3%

GILD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GILD quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin81.1%+1.3pp79.8%+0.9pp79.2%+2.3pp79.5%+0.4pp79.8%+0.7pp78.8%+1.0pp76.9%+0.1pp79.1%+8.5pp
Operating Margin41.7%-1.1pp-133.2%37.2%+3.6pp25.0%-7.4pp42.8%+31.1pp34.9%-3.1pp33.6%+98.2pp32.4%+9.7pp
Net Margin29.3%-10.0pp-134.5%29.0%+9.3pp27.6%+4.0pp39.3%+22.7pp27.7%+4.5pp19.7%+82.1pp23.6%+3.5pp
Return on Equity18.6%+4.5pp-88.7%-98.7pp8.6%+1.7pp9.6%+0.4pp14.2%+7.4pp10.0%+1.1pp6.9%+30.6pp9.2%+3.0pp
Return on Assets4.7%-0.5pp-21.3%-24.8pp3.6%+1.3pp3.7%+0.7pp5.2%+2.9pp3.5%+0.5pp2.3%+9.7pp3.0%+0.7pp
Current Ratio1.38-0.1x1.270.0x1.97+0.6x1.550.0x1.45+0.2x1.32+0.2x1.37+0.3x1.60+0.2x
Debt-to-Equity1.83+0.8x2.01+0.9x0.89-0.3x0.97-0.3x1.03-0.1x1.13-0.1x1.16-0.1x1.29+0.3x
Liabilities-to-Equity2.94+1.2x3.17+1.3x1.39-0.6x1.60-0.5x1.72-0.2x1.83-0.1x1.95-0.3x2.05+0.3x
Asset Turnover0.160.0x0.160.0x0.120.0x0.130.0x0.130.0x0.130.0x0.120.0x0.130.0x
FCF Margin57.8%+6.8pp44.0%+33.8pp34.9%+10.1pp39.4%+2.0pp51.0%-4.3pp10.2%-7.0pp24.8%-6.8pp37.4%+9.9pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Gilead Sciences Inc GILD FY2025 $29.4B $8.5B 28.9% $211.2B 66/100
Amgen Inc AMGN FY2025 $36.8B $7.7B 21.0% $247.7B 64/100
AstraZeneca PLC AZN FY2025 $58.7B $10.2B 17.4% $282.7B 63/100
Novartis AG NVS FY2025 $56.7B $14.0B 24.7% $300.5B 67/100
Merck & Co., Inc. MRK FY2025 $65.0B $18.3B 28.1% $353.4B 62/100
AbbVie Inc. ABBV FY2025 $61.2B $4.2B 6.9% $517.6B 59/100

Frequently Asked Questions

Gilead Sciences Inc (GILD) reported $29.4B in total revenue for fiscal year 2025. This represents a 2.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Gilead Sciences Inc (GILD) revenue grew by 2.4% year-over-year, from $28.8B to $29.4B in fiscal year 2025.

No, Gilead Sciences Inc (GILD) reported a net loss of $3.9B over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $8.5B, with a net profit margin of 28.9%.

Gilead Sciences Inc (GILD) reported diluted earnings per share of $6.78 for fiscal year 2025. This represents a 1684.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Gilead Sciences Inc (GILD) had EBITDA of $12.8B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Gilead Sciences Inc (GILD) had $7.6B in cash and equivalents against $22.1B in long-term debt.

Gilead Sciences Inc (GILD) had a gross margin of 78.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Gilead Sciences Inc (GILD) had an operating margin of 34.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Gilead Sciences Inc (GILD) had a net profit margin of 28.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Gilead Sciences Inc (GILD) paid $3.16 per share in dividends during fiscal year 2025.

Gilead Sciences Inc (GILD) has a return on equity of 37.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Gilead Sciences Inc (GILD) generated $9.5B in free cash flow during fiscal year 2025. This represents a -8.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Gilead Sciences Inc (GILD) generated $10.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Gilead Sciences Inc (GILD) had $59.0B in total assets as of fiscal year 2025, including both current and long-term assets.

Gilead Sciences Inc (GILD) invested $563.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Gilead Sciences Inc (GILD) invested $5.8B in research and development during fiscal year 2025.

Yes, Gilead Sciences Inc (GILD) spent $1.9B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Gilead Sciences Inc (GILD) had 1.24B shares outstanding as of fiscal year 2025.

Gilead Sciences Inc (GILD) had a current ratio of 1.55 as of fiscal year 2025, which is generally considered healthy.

Gilead Sciences Inc (GILD) had a debt-to-equity ratio of 0.97 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Gilead Sciences Inc (GILD) had a liabilities-to-equity ratio of 1.60 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Gilead Sciences Inc (GILD) had a return on assets of 14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Gilead Sciences Inc (GILD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $211.2B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Gilead Sciences Inc (GILD) trades at 6.8x sales, its market capitalization divided by $31.0B revenue, trailing 12 months to September 30, 2026. The market capitalization is $211.2B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Gilead Sciences Inc (GILD) has an Altman Z-Score of 5.01, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Gilead Sciences Inc (GILD) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Gilead Sciences Inc (GILD) has an earnings quality ratio of 1.18x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Gilead Sciences Inc (GILD) has an interest coverage ratio of 9.79x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Gilead Sciences Inc (GILD) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top